Trastuzumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the Her2/neu receptor, recommended to treat the ErbB2 positive breast cancer, as monotherapy or in combination with other chemotherapy for adjuvant or palliative treatment [55]. Here, ERBB2 is linked to breast cancer.